The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms promotes health and transforms OSA treatment

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care at the FDA’s Center for Drug Evaluation and Research.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it ... step forward for patients with obstructive sleep apnea,” Dr. Sally ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

The FDA approval for sleep apnea is based on ... "important risk factors for cardiovascular complications of obstructive sleep apnea with obesity," researchers wrote in the New England Journal ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.